1,176
Participants
Start Date
August 31, 2016
Primary Completion Date
January 31, 2017
Study Completion Date
January 31, 2017
GSP 301 NS
2 spray in each nostril twice daily for 14 days
GOM-NS
2 spray in each nostril twice daily for 14 days
GMM-2 NS
2 spray in each nostril twice daily for 14 days
GSP 301 placebo NS
2 spray in each nostril twice daily for 14 days
Investigational Site 406, Mission Viejo
Investigational Site 414, Orange
Investigational Site 435, San Diego
Investigational Site 420, Centennial
Investigational Site 444, Colorado Springs
Investigational Site 428, Aventura
Investigational Site 412, Miami
Investigational Site 436, Bethesda
Investigational Site 432, South Dartmouth
Investigational Site 426, Minneapolis
Investigational Site 403, Plymouth
Investigational Site 443, Columbia
Investigational Site 441, Rolla
Investigational Site 440, St Louis
Investigational Site 405, Bellevue
Investigational Site 434, Skillman
Investigational Site 408, Rochester
Investigational Site 418, Rockville Centre
Investigational Site 402, High Point
Investigational Site 427, Raleigh
Investigational Site 419, Cincinnati
United States 404, Cincinnati
United States 407, Edmond
Investigational Site 410, Oklahoma City
Investigational Site 424, Tulsa
Investigational Site 411, Pittsburgh
Investigational Site 416, Spartanburg
Investigational Site 415, Austin
Investigational Site 442, Austin
Investigational Site 417, Boerne
Investigational Site 421, Dallas
Investigational Site 430, Dallas
Investigational Site 431, El Paso
Investigational Site 433, Kerrville
Investigational Site 422, New Braunfels
Investigational Site 401, San Antonio
Investigational Site 413, San Antonio
Investigational Site 425, San Antonio
Investigational Site 437, San Antonio
Investigational Site 400, Waco
Investigational Site 409, Waco
Investigational Site 423, Draper
Investigational Site 439, Greenfield
Glenmark Specialty S.A.
INDUSTRY